This Week in Hematology — Jun 10, 2026

Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning advances in allogeneic transplant strategies, the growing role of molecular biomarkers in managing hematologic malignancies, and new therapeutic approaches for benign and genetic blood disorders. Let's dive in.

First up, we have two papers looking at optimizing allogeneic stem cell transplantation, one focusing on donor selection and the other on a challenging new indication. In Blood Advances, the BMT Clinical Trials Network reports the results of the BMT CTN 1702 trial, a large, prospective study designed to answer a critical question: how do outcomes from HLA-mismatched donors compare to those from matched unrelated donors, or MUDs? [4]. The trial enrolled nearly 1200 patients who lacked a matched sibling donor and used a prognostic score to assign them to either a MUD or their center's preferred alternative, which could be a haploidentical-related donor, a mismatched unrelated donor, or umbilical cord blood. The key finding is that for overall survival, there was no statistically significant difference between using a MUD and using either a haploidentical or a mismatched unrelated donor. However, umbilical cord blood transplants fared significantly worse, associated with more than double the risk of death and more than triple the risk of treatment-related mortality compared to MUDs. The risk of relapse was similar across all donor types. It's worth noting that post-transplant cyclophosphamide, or PTCy, was used in the vast majority of haploidentical and mismatched unrelated donor transplants. In a sub-analysis of patients receiving PTCy, the haploidentical and mismatched unrelated donors were associated with a higher risk of severe acute and chronic GVHD, but other outcomes remained similar to MUDs. The clinical takeaway here is clear: for patients who need a transplant urgently, haploidentical or mismatched unrelated donors are effective alternatives that can expedite the process without compromising survival, though clinicians should be prepared for a higher risk of GVHD. Complementing this, a study in the American Journal of Hematology provides comparative data on treatments for VEXAS syndrome, a recently described and severe inflammatory condition [6]. Investigators conducted a multicenter, retrospective analysis of 66 patients treated with either hypomethylating agents, or HMAs, or with allogeneic hematopoietic stem cell transplant. While the HMA group was slightly older, other baseline characteristics were well-balanced. The outcomes, however, were starkly different. Among evaluable patients, all who underwent transplant achieved molecular remission, and 58% were able to discontinue glucocorticoids. In contrast, HMA therapy led to molecular remission in only 22% of patients and steroid discontinuation in just 6%. On multivariable analysis adjusted for age and comorbidities, allogeneic transplant was associated with an 80% reduction in the risk of death compared to HMAs. While limited by its retrospective design, this study provides compelling evidence that allogeneic transplant is an attractive and potentially curative strategy that should be strongly considered for eligible patients with VEXAS syndrome.

Next, two studies highlight how molecular monitoring is refining risk stratification and response assessment in both myeloid and lymphoid malignancies. In a large study published in Blood, the PETHEMA group investigated the prognostic impact of variant allele frequency, or VAF, in nearly 700 patients with intensively treated NPM1-mutated AML [9]. While NPM1-mutated AML is often considered a favorable-risk group, outcomes are heterogeneous. This study shows that quantitative features of the mutation provide much deeper prognostic insight. The investigators identified a VAF cutoff of just over 31 percent. Counterintuitively, patients with a *low* NPM1 VAF had significantly worse overall and relapse-free survival, with about a 50% increased risk of death. The VAF of co-mutations also mattered immensely; for instance, a high VAF of DNMT3A or KRAS was adverse, whereas a high VAF of IDH2 was protective. The study also delved into clonal architecture, finding that the co-localization of an NPM1 mutation with a WT1 mutation on the same clone predicted a dismal prognosis. The message for clinicians is that we need to move beyond simply identifying the presence of an NPM1 mutation. Its quantitative burden and clonal context are critical for accurate risk stratification. Shifting to lymphoid malignancies, a paper in the American Journal of Hematology explores the use of cerebrospinal fluid circulating tumor DNA, or CSF ctDNA, as a biomarker in primary central nervous system lymphoma [2]. In a prospective study, researchers performed serial CSF ctDNA monitoring in patients receiving R-MO induction therapy. They found that achieving clearance of ctDNA mid-treatment was a powerful predictor of both complete response and superior progression-free survival. Importantly, this molecular clearance showed stronger predictive value than interim PET-CT scans. This supports the growing body of evidence that CSF ctDNA is a highly promising, minimally invasive tool for early response assessment in PCNSL, one that could potentially allow for therapy adjustments much earlier than traditional imaging.

Finally, we turn to non-malignant hematology, with a study on a new option for autoimmune hemolysis and an update on a gene therapy for thalassemia. In Blood Advances, a prospective, single-center trial evaluated sirolimus for adults with relapsed or refractory warm autoimmune hemolytic anemia or Evans' syndrome [5]. In a cohort of 78 patients, sirolimus demonstrated impressive efficacy. At 6 months, the overall response rate was just over 80 percent, with more than half of patients achieving a complete response. These responses proved durable, with similar rates seen at the 12-month mark. The treatment was also well-tolerated, with most adverse events being mild and reversible. For a patient population with limited effective therapeutic options, these findings support sirolimus as a clinically meaningful, steroid-sparing alternative for both steroid-dependent and steroid-refractory disease. And in the American Journal of Hematology, we get a deeper look at the physiological effects of exagamglogene autotemcel, or exa-cel, the CRISPR-based gene therapy for transfusion-dependent beta-thalassemia [10]. We already know from the pivotal CLIMB THAL-111 trial that exa-cel leads to transfusion independence in over 90 percent of patients. This new report analyzes secondary and exploratory endpoints from that trial and its long-term follow-up study, focusing on erythropoiesis and iron homeostasis. The data show that following treatment, as patients became transfusion independent, their levels of erythroferrone decreased and hepcidin normalized. This is a critical finding, as it indicates a correction of the underlying ineffective erythropoiesis that drives the pathophysiology of the disease. Further supporting this, other biomarkers like erythropoietin and soluble transferrin receptor also trended toward normalization. Consequently, markers of iron overload decreased and then remained stable, even after 68 percent of participants were able to discontinue iron chelation therapy. This demonstrates that exa-cel does more than just raise hemoglobin levels; it appears to fundamentally restore effective erythropoiesis and normal iron regulation, offering a much deeper correction of the disease.

If you only have time for one paper this week, make it the BMT CTN 1702 trial on donor sources in Blood Advances [4]. This large, prospective study provides the high-quality evidence we've needed to confidently use haploidentical or mismatched unrelated donors when a matched unrelated donor isn't quickly available, clarifying that these options offer similar survival outcomes while highlighting the inferiority of cord blood in this context.

Here are the key takeaways from this week in Hematology. First, for allogeneic transplant, haploidentical or mismatched unrelated donors are valid alternatives to matched unrelated donors, offering similar survival outcomes, though potentially with more GVHD. Umbilical cord blood, however, was associated with significantly worse survival and should be used with caution [4]. Second, in VEXAS syndrome, allogeneic transplant appears superior to hypomethylating agents, offering higher rates of molecular remission, steroid discontinuation, and improved overall survival in eligible patients [6]. Third, for NPM1-mutated AML, don't just look at the mutation status. A low NPM1 variant allele frequency, along with the VAF of co-mutations, can predict inferior survival, adding a crucial quantitative layer to risk stratification [9]. Fourth, in managing primary CNS lymphoma, monitoring CSF circulating tumor DNA for clearance may be a more sensitive and earlier predictor of response and progression-free survival than interim PET-CT scans [2]. And finally, consider sirolimus as an effective and safe steroid-sparing option for patients with relapsed or refractory warm autoimmune hemolytic anemia or Evans' syndrome, with high and durable response rates [5].

That's your roundup for This Week in Hematology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.